title: [Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
abstract: This study investigated the relationship between quality of life (QOL) and efficacy or occurrence of adverse events in patients who were administered lenalidomide and dexamethasone (Len+Dex) therapy for relapsed or refractory multiple myeloma (MM) in the hematology department at Obihiro Kosei Hospital from September 2010 to September 2012. QOL was evaluated using a quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD). The average QOL score of 7 patients receiving 4 cycles of Len+Dex treatment decreased 5 points from baseline Len+Dex treatment. The change in QOL score was significantly correlated with changes in serum M-protein (correlation coefficient: R=0.777). However, there was no significant correlation between adverse events and the change in QOL score. Our results indicate that QOL may be improved by the effects of Len+Dex treatment.
authors.affiliation: Dept. of Pharmacy, Obihiro Kosei General Hospital.
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Sato
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Namiko
authors.initials: N
authors.lastname: Oi
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Namba
authors.forename: Yuto
authors.initials: Y
authors.lastname: Taniguchi
authors.forename: Hiroko
authors.initials: H
authors.lastname: Yahata
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Komori
authors.forename: Hajime
authors.initials: H
authors.lastname: Kobayashi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide